Daniel C. Chung

Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

Stephen R. Russell, Jean Bennett, Jennifer Wellman et al. · The Lancet · 2017 · 1.9K citations

Medicine, Ophthalmology, Vision Science +14

Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial

Albert M. Maguire, Katherine A. High, Alberto Auricchio et al. · The Lancet · 2009 · 858 citations

Medicine, Genetics, Molecular Genetics +12

Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research

Rebecca C. Fitzgerald, Richard Hardwick, David G. Huntsman et al. · Journal of Medical Genetics · 2010 · 542 citations · Full text

Medicine, Genetics, Oncology +17

An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia

Yair Benita, Hirotoshi Kikuchi, Andrew D. Smith et al. · Nucleic Acids Research · 2009 · 477 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial

Jean Bennett, Jennifer Wellman, Kathleen Marshall et al. · The Lancet · 2016 · 456 citations · Full text

Medicine, Genetics, Ophthalmology +16